Sagimet Biosciences Inc. (SGMT)

Revenue by Product

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2023
Period Ending	Dec 31, 2023
Therapeutics for the Treatment of Metabolic Dysfunction-associated Steatohepatitis and Other Diseases	2.00M

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2023
Period Ending	Dec 31, 2023
United States	2.00M